These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24700299)

  • 1. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.
    Abdul-Jalil KI; Sheehan KM; Toomey S; Schmid J; Prehn J; O'Grady A; Cummins R; O'Neill B; McNamara DA; Deasy J; Breathnach O; Grogan L; Rogers A; Doherty G; Winter D; Ryan J; El-Masry S; Gibbons D; Sheahan K; Gillen P; Kay EW; Hennessy BT
    Ann Surg Oncol; 2014 Aug; 21(8):2642-9. PubMed ID: 24700299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
    Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
    Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
    Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
    Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The depth of post-treatment perirectal tissue invasion is a predictor of outcome in patients with clinical T3N1M0 rectal cancer treated with neoadjuvant chemoradiation followed by surgical resection.
    Brandt WS; Yong S; Abood G; Micetich K; Walther A; Shoup M
    Am J Surg; 2014 Mar; 207(3):357-60; discussion 360. PubMed ID: 24456833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
    Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
    Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
    Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
    Mawdsley S; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Osborne M; Livingstone JI; MacDonald P; Mitchell IC; Meyrick-Thomas J; Northover JM; Windsor A; Novell R; Wallace M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):745-52. PubMed ID: 16199310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
    Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutations predict local recurrences in rectal cancer patients.
    He Y; Van't Veer LJ; Mikolajewska-Hanclich I; van Velthuysen ML; Zeestraten EC; Nagtegaal ID; van de Velde CJ; Marijnen CA
    Clin Cancer Res; 2009 Nov; 15(22):6956-62. PubMed ID: 19903786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
    Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
    Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
    Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
    Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy.
    Pacelli F; Tortorelli AP; Rosa F; Bossola M; Sanchez AM; Papa V; Valentini V; Doglietto GB
    Ann Surg Oncol; 2010 Jan; 17(1):152-62. PubMed ID: 19834766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: are they comparable?
    Huh JW; Kim CH; Kim HR; Kim YJ
    Surgery; 2011 Nov; 150(5):980-4. PubMed ID: 21875732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
    Tsutsumi S; Tabe Y; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Shioya M; Saito J; Asao T; Nakano T; Kuwano H
    Anticancer Res; 2011 Nov; 31(11):3963-7. PubMed ID: 22110227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.